Fig. 1: Vaccine effectiveness against symptomatic infection. | Nature Microbiology

Fig. 1: Vaccine effectiveness against symptomatic infection.

From: Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

Fig. 1

a–f, Adjusted vaccine effectiveness estimates of BNT162b2 (Pfizer-BioNTech Comirnaty), mRNA-1273 (Moderna Spikevax) and ChAdOx1 (AstraZeneca Vaxzevria) vaccines ≥14 d after the first dose (for individuals who received only one dose) and ≥7 d after the second dose against symptomatic SARS-CoV-2 infection caused by Alpha (a), Beta (b), Gamma (c), Beta/Gamma (d), Delta (e) and non-VOC (f) SARS-CoV-2 between 14 December 2020 and 3 August 2021 in Ontario, Canada; n = 44,688 test-positive Alpha, n = 378 test-positive Beta, n = 1,969 test-positive Gamma, n = 1,269 test-positive Beta/Gamma, n = 3,136 test-positive Delta and n = 31,440 test-positive non-VOC SARS-CoV-2 symptomatic cases, and n = 599,191 symptomatic test-negative controls. Data are presented as effectiveness point estimates, with error bars indicating the corresponding 95% CIs. Asterisks indicate vaccine effectiveness estimated as 100% on the basis of zero vaccinated test-positive cases.

Source data

Back to article page